HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Martz, E. Articles by Benacerraf, B. Search for Related Content PubMed Articles by Martz, E. Articles by Benacerraf, B.

An Effector-Cell Independent Step in Target Cell Lysis by Sensitized Mouse Lymphocytes¹

From the Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115

Abstract

Heparin was previously shown to inhibit the lysis of target cells by sensitized thymus-derived mouse lymphocytes in vitro. However, heparin failed to inhibit target cell lysis when added to the cultures after only 10% specific release of chromium-51 had occurred. For further exploration of this phenomenon, effector cells have been specifically inactivated at various times during their action on target cells. This was accomplished with alloantiserum made in target strain mice (DBA/2) against effector strain cells (C57BL/6). Treatment of effector cells with this antiserum and complement rendered them unable to initiate new cytolytic events on target cells (and incidentally did not release soluble toxins). However, when untreated cultures were incubated for about 60 min, after which the effector cells had caused 10% specific release of chromium-51 from the target population, treatment of the cultures with anti-effector serum and complement did not interfere with the subsequent lysis of more than half of the target cell population. Hence, the effector-dependent action on the target cell is completed much earlier than evidenced by chromium-51 release, and subsequent, effectorindependent steps must occur before completion of target cell lysis. Data suggest that divalent cations are required for the effector-dependent phase, but not for the effector-independent phase.

Footnotes

¹ Supported by grants from the New York Cancer Research Institute, Inc. and the Council for Tobacco Research—U. S. A., Inc.

² Post-doctoral trainee of the National Institutes of Health.